首页> 外文期刊>Journal of Drug Delivery and Therapeutics >Artificial cell microcapsule for oral delivery of thalidomide: design, preparation, and in-vitro characterization for Crohn’s disease application
【24h】

Artificial cell microcapsule for oral delivery of thalidomide: design, preparation, and in-vitro characterization for Crohn’s disease application

机译:口服沙利度胺的人造细胞微胶囊:克罗恩病应用的设计,制备和体外表征

获取原文
           

摘要

Crohn's disease is a chronic inflammatory disorder of the gut and is classified as a type of inflammatory bowel disease. The anti-inflammatory drug thalidomide has shown to be very effective against Crohn’s disease, but presents several limitations such as drowsiness, skin rash and hypertension. Therefore, development of novel delivery system is urgent and necessary. The aim of this paper is to present the formulation of Alginate- Poly-L-Lysine-Alginate (APA) microcapsules for the delivery of thalidomide to desired locations of the gastrointestinal tract. APA microcapsules were designed, prepared and characterized in-vitro for thalidomide release. Mechanical stability of capsules and the drug release profile were monitored in a simulated gastrointestinal model. Data suggest that APA microcapsules enable a slow release of thalidomide in a pH and time-dependent manner. Indeed, the characteristics of APA microcapsules make it a suitable carrier for the targeted delivery of thalidomide to specific areas of the gastrointestinal tract.
机译:克罗恩氏病是肠道的一种慢性炎症性疾病,被归类为一种炎症性肠病。抗炎药沙利度胺对克罗恩病非常有效,但存在嗜睡,皮疹和高血压等多种局限性。因此,开发新型的传送系统是当务之急。本文的目的是提出用于将沙利度胺递送至胃肠道所需位置的藻酸盐-聚-L-赖氨酸-藻酸盐(APA)微胶囊的制剂。设计,制备和表征了APA微囊,用于沙利度胺的体外释放。在模拟的胃肠道模型中监测胶囊的机械稳定性和药物释放曲线。数据表明,APA微胶囊能够以pH和时间依赖性方式缓慢释放沙利度胺。实际上,APA微胶囊的特性使其成为将沙利度胺有针对性地输送至胃肠道特定区域的合适载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号